Q-omics provides the consensus-scored MAFF profile across patient tissues and cancer cell-line models. MAFF expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MAFF is differentially expressed in 10, with the highest sampling consensus in BLCA. Additionally, MAFF RNA expression shows 16,695 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and BLCA as cancer lineages where MAFF shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAFF — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAFF survival associations across molecular data types. MAFF RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAFF RNA expression–survival associations across cancer types. High MAFF expression shows unfavorable associations in ACC, LUAD, HNSC, PAAD, KIRP and OV. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MAFF RNA expression.
This table summarizes MAFF tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MAFF. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAFF shows lower tumor expression in BLCA, UCEC, LUAD, BRCA, KICH and LUSC. The BLCA box plot shows higher MAFF RNA expression in normal versus tumor tissue (log2 FC = −1.798, t-test p < 0.001).
This table shows molecular features associated with MAFF in patient tissues and cancer cell lines. In patient samples, MAFF shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MAFF RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
